The Starpharma Ltd (ASX: SPL) share price has jumped 8% higher in early trade after the company provided an update on its phase 1/2 clinical trial for its colorectal cancer drug, DEP irinotecan.
What did Starpharma say in its latest update?
Starpharma said that it has received the necessary regulatory and ethics approvals and will commence its phase 1/2 clinical trial for DEP irinotecan.
According to the release, the objectives of the trial are to evaluate the safety, tolerability, and pharmacokinetics (looking at the way the drug moves through the body) of DEP irinotecan to define a recommended phase 2 dose (RP2D) and to determine anti-tumour efficacy of the product in select tumour types.
DEP irinotecan is the third DEP product to enter the clinic